Parallel Advisors’s Immunovant IMVT Stock Holding History

Parallel Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.68K	Hold	108	–	–	﹤0.01%	3275
2025 Q4	$2.75K	Buy	108 +26	+32%	+$580	﹤0.01%	3045
2025 Q3	$1.32K	Sell	82 -1,224	-94%	-$19.8K	﹤0.01%	3150
2025 Q2	$20.9K	Buy	1,306 +1,299	+18,557%	+$19.6K	﹤0.01%	2171
2025 Q1	$120	Sell	7 -31	-82%	-$648	﹤0.01%	3429
2024 Q4	$941	Buy	+38	New	+$1.08K	﹤0.01%	3121
2023 Q2	–	Sell	-24	Closed	-$372	–	3446
2023 Q1	$372	Hold	24	–	–	﹤0.01%	3193
2022 Q4	$426	Hold	24	–	–	﹤0.01%	3062
2022 Q3	$0	Buy	+24	New	+$117	﹤0.01%	3314
2022 Q1	–	Sell	-382	Closed	-$3K	–	3105
2021 Q4	$3K	Buy	+382	New	+$3.15K	﹤0.01%	2579
2021 Q3	–	Sell	-14,262	Closed	-$151K	–	3160
2021 Q2	$151K	Hold	14,262	–	–	0.01%	803
2021 Q1	$229K	Buy	+14,262	New	+$376K	0.01%	593

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Parallel Advisors's IMVT Position: Q1 2026 in Review

Parallel Advisors held its Immunovant (IMVT) position steady in Q1 2026 at 108 shares worth $2.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Parallel Advisors first reported a position in IMVT in Q1 2021 and has held it in 12 quarters since. The position peaked at $229K in Q1 2021. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Parallel Advisors held 108 shares of Immunovant worth $2.68K as of Q1 2026.
Parallel Advisors left its Immunovant share count unchanged in Q1 2026.
Immunovant made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3275 holding.
Parallel Advisors first reported a position in Immunovant in Q1 2021 and has held it in 12 quarters since.
Parallel Advisors's Immunovant position peaked at $229K in Q1 2021.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.